Lakewood-Amedex Biotherapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
LABT$0.39-28.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. | |
| By: | /s/ Kelvin Cooper |
| Name: | Kelvin Cooper |
| Title: | Chief Executive Officer (Principal Executive Officer) |
| By: | /s/ Peter Ceccacci |
| Name: | Peter Ceccacci |
| Title: | Chief Financial Officer |
| (Principal Financial Officer) |
Dated: August 13, 2026
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.